Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
164
Not yet recruiting, industry sponsors, Oncology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting600
- Completed2,063
164 trials
Showing 1 to 25, recently updated first.
- A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07951463 · 375 participants (planned) · Start Dec 31, 2026 · Primary completion Apr 30, 2029
Drug: Glumetinib Tablets; Placebo and 3 more · For: Non-small Cell Lung Cancer
- A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Wayshine Biopharm, Inc.Industry
NCT07948408 · 196 participants (planned) · Start Dec 10, 2026 · Primary completion May 1, 2028
Drug: WSD0922-FU; Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin) · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
- A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)Pivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947121 · 700 participants (planned) · Start Dec 25, 2026 · Primary completion Feb 24, 2031
Drug: Ris-Rez; Atezolizumab and 3 more · For: Lung Neoplasm
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07903506 · 750 participants (planned) · Start Feb 2027 · Primary completion Mar 2039
Drug: Anitocabtagene Autoleucel; Isatuximab and 6 more · For: Newly Diagnosed Multiple Myeloma
- A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07740720 · 100 participants (planned) · Start Dec 17, 2026 · Primary completion Mar 13, 2030
Drug: Dostarlimab · For: Neoplasms, Rectal
Sites: Fukuoka, Japan
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Pivotal-lookingNot yet recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07791732 · 600 participants (planned) · Start Mar 31, 2027 · Primary completion Jul 1, 2029
Drug: R-DXd; Bevacizumab · For: Fallopian Tube Cancer; Primary Peritoneal Cancer; High-Grade Serous Ovarian Cancer and 1 more
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Pivotal-lookingNot yet recruiting
Novatek PharmaceuticalsIndustry
NCT07935928 · 381 participants (planned) · Start Jan 2027 · Primary completion Dec 2029
Drug: NP-101; Ipi/Nivo · For: Gastroenteropancreatic Neuroendocrine Tumors
- SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III StudyPivotal-lookingNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07895992 · 490 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 30, 2028
Drug: SHR-A2009 + bevacizumab; Sacituzumab Tirumotecan · For: Non-squamous Non-small Cell Lung Cancer
Sites: Guangzhou, China
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07933432 · 300 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 14, 2029
Drug: QLS4131; Pomalidomide Capsules and 3 more · For: Relapsed or Refractory Multiple Myeloma
- [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain MetastasesPivotal-lookingNot yet recruiting
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
NCT07931261 · 381 participants (planned) · Start Dec 2026 · Primary completion Apr 2028
Drug: Floretyrosine F 18 ([18F]FET) · For: Brain Metastasis; Radiation Necrosis; Pseudoprogression and 1 more
- Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving SurgeryPivotal-lookingNot yet recruiting
SURGE TherapeuticsIndustry
NCT07723469 · 400 participants (planned) · Start Dec 2026 · Primary completion Oct 2034
Drug: BCS + SRG-514 · For: TNBC - Triple-Negative Breast Cancer
Sites: Rochester, Minnesota; New York, New York; Durham, North Carolina
- A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigPivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07929051 · 68 participants (planned) · Start Mar 4, 2027 · Primary completion Jul 3, 2028
Drug: Obrixtamig; Ezabenlimab and 3 more · For: Advanced Cancer
Sites: Ghent, Belgium; Bordeaux, France; Bron, France · 15 sites in all
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerPivotal-lookingNot yet recruiting
PfizerPfizer (PFE)
NCT07890597 · 3,800 participants (planned) · Start Dec 1, 2026 · Primary completion Apr 13, 2032
Drug: Atirmociclib; giredestrant · For: Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07924111 · 585 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2029
Drug: SYS6010; SG001 and 2 more · For: Esophageal Squamous Cell Carcinoma
- A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07926048 · 420 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Drug: QLS5132; Liposomal Doxorubicin and 2 more · For: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal CancerPivotal-lookingNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07917468 · 500 participants (planned) · Start Nov 25, 2026 · Primary completion Mar 25, 2030
Drug: Oxaliplatin; Placebo and 2 more · For: Locally Advanced Rectal Cancer
Sites: Guangzhou, China
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligiblePivotal-lookingNot yet recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07903272 · 1,000 participants (planned) · Start Dec 14, 2026 · Primary completion Jan 11, 2037
Drug: Ramantamig; Daratumumab and 4 more · For: Multiple Myeloma
- GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerPivotal-lookingNot yet recruiting
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07913360 · 368 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: GFH375 + Cetuximab; Fruquintinib and 1 more · For: Colorectal Cancer
- HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 MutationsPivotal-lookingNot yet recruiting
HutchmedIndustry
NCT07912398 · 210 participants (planned) · Start Nov 2026 · Primary completion Mar 2032
Drug: HMPL-306 tablet; Placebo · For: Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07910903 · 320 participants (planned) · Start Dec 2026 · Primary completion May 2030
Drug: CM336; CM313 and 3 more · For: Multiple Myeloma (MM)
Sites: Tianjin, China
- A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07908537 · 564 participants (planned) · Start Dec 7, 2026 · Primary completion Dec 8, 2031
Drug: Gocatamig; Durvalumab and 1 more · For: Small Cell Lung Cancer
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaPivotal-lookingNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07691762 · 690 participants (planned) · Start Nov 2026 · Primary completion Sep 2031
Drug: SHR-8068 + Adebrelimab + Bevacizumab; SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo and 1 more · For: Hepatocellular Carcinoma
Sites: Nanjing, China; Shanghai, China
- Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenPivotal-lookingNot yet recruiting
Precigen, IncIndustry
NCT07901738 · 15 participants (planned) · Start Dec 31, 2026 · Primary completion Jan 2029
Drug: Zopapogene imadenovec-drba · For: Recurrent Respiratory Papillomatosis (RRP); Juvenile-onset Recurrent Respiratory Papillomatosis; Papillomavirus Infections
Sites: Washington D.C., District of Columbia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.